Abstract

BackgroundSurgical revision concepts for the treatment of aseptic humeral, femoral, and tibial diaphyseal nonunion were evaluated. It was analyzed if the range of time to bone healing was shorter, and if clinical and radiological long-term outcome was better following application of additional recombinant human Bone Morphogenetic Protein-7 (rhBMP-7) compared to no additional rhBMP-7 use.MethodsIn a retrospective comparative study between 06/2006 and 05/2013, 112 patients diagnosed with aseptic diaphyseal humerus (22 patients), femur (41 patients), and tibia (49 patients) nonunion were treated using internal fixation and bone graft augmentation. For additional stimulation of bone healing, growth factor rhBMP-7 was locally administered in 62 out of 112 patients. Follow-up studies including clinical and radiological assessment were performed at regular intervals as well as after at least one year following nonunion surgery.ResultsOne hundred and two out of 112 (humerus: 19, femur: 37, tibia: 47) nonunion healed within 12 months after revision surgery without any significant differences between the cohort groups. According to the DASH outcome measure for the humerus (p = 0.679), LEFS for the femur (p = 0.251) and the tibia (p = 0.946) as well as to the SF-12 for all entities, no significant differences between the treatment groups were found.ConclusionsAseptic diaphyseal nonunion in humerus, femur, and tibia healed irrespectively of additional rhBMP-7 application. Moreover, the results of this study suggest that successful nonunion healing can be linked to precise surgical concepts using radical removal of nonunion tissue, stable fixation and restoration of axis, length and torsion, rather than to the additional use of signaling proteins.Trial registrationThis clinical trial was conducted according to ICMJE guidelines as well as to the approval of the National Medical Board (Ethics Committee of the Bavarian State Chamber of Physicians; TRN: 2016-104) and has been retrospectively registered with the German Clinical Trails Register (TRN: DRKS00012652).

Highlights

  • Surgical revision concepts for the treatment of aseptic humeral, femoral, and tibial diaphyseal nonunion were evaluated

  • A total of 62 patients obtained biological augmentation using autologous bone grafting with additional application of one unit of recombinant human Bone Morphogenetic Protein recombinant human Bone Morphogenetic Protein-7 (rhBMP-7) (Eptotermine-α, OP-1®; Stryker Biotech, Kalamazoo, MI, USA) according to manufacturer’s instructions (3.3 mg of lyophilized rhBMP-7 combined with 6.7 mg of bovine collagen type I) in each case

  • Thirteen out of 22 patients were treated using rigid LC plating with autologous cancellous bone grafting, and additional application of rhBMP-7

Read more

Summary

Introduction

Surgical revision concepts for the treatment of aseptic humeral, femoral, and tibial diaphyseal nonunion were evaluated. It was analyzed if the range of time to bone healing was shorter, and if clinical and radiological long-term outcome was better following application of additional recombinant human Bone Morphogenetic Protein-7 (rhBMP-7) compared to no additional rhBMP-7 use. Open fractures of the tibia are often associated with complex soft tissue lesions [5]. Another key factor that delays bone healing may be the absence of loading. Smoking and nicotine abuse directly correlate with delayed bone healing and increased failure rates after operative nonunion revision using autologous bone grafting [9]. Increased patients’ age adversely affects physiological osseous healing [10]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call